Today's Hours: 12:00pm - 8:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Harvinder Singh Gill, Richard W. Compans, editors.
    Summary: "This book introduces nanoparticles as a powerful platform for vaccine design. Current challenges in vaccine development are discussed and the unique advantages nanoparticles provide in overcoming these challenges are explored. The authors offer fascinating insights into the immunological assets of using nanoparticles as delivery vehicles or adjuvants and present different materials that are being used in nanoparticle-based vaccine development, covering peptides, proteins, polymers, virus-like particles, and liposomes. Its contemporary research insights and practical examples for applications make this volume an inspiring read for researchers and clinicians in vaccinology and immunology. Chapter "Liposome Formulations as Adjuvants for Vaccines" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com."--Publisher's description.

    Contents:
    Liposome formulations as adjuvants for vaccines / Mangala Rao, Kristina K. Peachman, and Carl R. Alving
    Polymeric nanoparticle-based vaccine adjuvants and delivery vehicles / Elizabeth A. Grego, Alaric C. Siddoway, Metin Uz, Luman Liu, John C. Christiansen, Kathleen A. Ross, Sean M. Kelly, Surya K. Mallapragada, Michael J. Wannemuehler, and Balaji Narasimhan
    Virus-like particle vaccines against respiratory viruses and protozoan parasites / Ki-Back Chu and Fu-Shi Quan
    Protein and peptide nanocluster vaccines / Timothy Z. Chang and Julie A. Champion.
    Digital Access Springer 2021
    Access via Current topics in microbiology and immunology ; 2021; 433.
    Location
    Version
    Call Number
    Items
    Current topics in microbiology and immunology ; 2021; 433.
    2021
  • Article
    Gillies AH, Morgan TO.
    Br J Clin Pharmacol. 1978 Oct;6(4):357-62.
    1. A double-blind comparison of the effect of tienylic acid and hydrochlorothiazide on blood pressure was made in patients with moderate hypertension. 2. The antihypertensive effect of 500 mg tienylic acid was comparable to 100 mg hydrochlorothiazide; mean decrease in supine blood pressure after 6 weeks treatment was 20/12 mmHg with tienylic acid and 17/9 mmHg with hydrochlorothiazide. Onset of antihypertensive action was within 1 week and was associated with significant weight loss. 3. Tienylic acid caused a marked decrease in serum uric acid to a mean of 0.18 mmol/1 (n = 11, P less than 0.001), this persisted through the treatment period and returned to placebo values 1 week after treatment ceased. Some patients had uric acid crystaluria and some had post-treatment uric acid levels higher than on placebo. 4. Tineylic acid and hydrochlorothiazide caused mild hypokalemia and alkalosis with proportional decrease in plasma chloride. 5. Blood urea and serum creatinine rose with both drugs and there was an unimportant decline in plasma sodium. 6. Tienylic acid is an effective antihypertensive agent with powerful uricosuric action and appears relatively free of side effects. Further studies are necessary to determine optimal dosage regimes and long term safety.
    Digital Access Access Options